Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells.

Abstract

Connexin 26 (Cx26) encodes a gap junction protein and is a putative tumor suppressor gene. We evaluated the effect of forced expression of Cx26 on three human prostate cancer cell lines, PC-3, LNCap, and DU-145. The three cell lines were infected with a Cx26 adenovirus vector (Ad-Cx26) or a control vector or were mock infected. We tested cell growth, cell cycle, apoptosis, and the efficacy of combined treatment with doxorubicin. Ad-Cx26 infection suppressed the growth of all the cell lines compared with controls and induced cell cycle arrest at the G2/M phase and apoptosis. Ad-Cx26 decreased the expression of Bcl-2. LNCaP cell growth was dramatically suppressed by Ad-Cx26 alone. PC-3 and DU-145 had greater growth suppression with combined gene therapy and chemotherapy than with either Ad-Cx26 or doxorubicin alone. Forced expression of Cx26 suppresses the growth of prostate cancer cells and decreases the expression of Bcl-2. Combining Cx26 gene therapy with doxorubicin results in greater growth suppression.

• Authors: Motoyoshi Tanaka, H Barton Grossman
• Journal: Oncology reports (Oncol Rep) Vol. 11 Issue 2 Pg. 537-41 (Feb 2004) ISSN: 1021-335X [Print] Greece
• PMID: 14719096 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Connexins
• GJB2 protein, human
• Proto-Oncogene Proteins c-bcl-2
• Connexin 26
• Doxorubicin

Topics

• Antineoplastic Agents (toxicity)
• Apoptosis (physiology)
• Cell Division (physiology)
• Cell Line, Tumor
• Connexin 26
• Connexins (physiology)
• Doxorubicin (toxicity)
• Gene Expression Regulation, Neoplastic (drug effects)
• Genetic Therapy
• Humans
• Male
• Prostatic Neoplasms
• Proto-Oncogene Proteins c-bcl-2 (genetics)